Charles DeBattista
Academic Appointments
- Professor - Med Center Line, Psychiatry & Behavioral Science - Psychopharmacology
Contact Information
-
Clinical Offices
Psychiatry Department 401 Quarry Rd MC 5723 Stanford, CA 94305-5723 Tel Work (650) 723-8335 Fax (650) 724-9900
Professional Snapshot
Clinical Focus
- Psychiatry
Honors and Awards
- America's Best Doctors; Psychiatry, Best Doctors (2009-2010)
- Review Article of the Year, Primary Psychiatry (2004)
- Teacher of the Year, Dept. Of Psychiatry (1998, 2000, 2001)
Professional Education
| Board Certification: | Psychiatry, American Board of Psychiatry and Neurology (1995) |
| Fellowship: | Stanford University Medical Center, CA (1993) |
| Residency: | Stanford University Medical Center, CA (1993) |
| Internship: | Stanford University Medical Center, CA (1990) |
| Medical Education: | UCSF School of Medicine, CA (1989) |
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | BMS, Lilly, Wyeth |
| Equity: | Corcept |
Scientific Focus
Research Interests
Treatment resistant depression.
Novel biological interventions in the treatment of mental illness.
Anti-glucocorticoid drugs in the treatment of mood disorders.
Augmentation strategies in the treatment of depression.
Clinical Trials
- A Twelve Month, Open-Label, Safety Trial of Flibanserin 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire Disorder Recruiting
- rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure No longer recruiting
- A safety and efficacy trial of flibanserin in premenopausal women with HSDD No longer recruiting
- Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression Completed
Publications
- Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs. 2009; (5): 369-77
- Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Psychoneuroendocrinology. 2009; (7): 1012-8
- A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials. 2009; (4): 284-8
- Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008; (4): 395-404
- Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007 Jul-Sep; (3): 153-9
Help